← Eichor
Study identifier: NCT07083960 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

OM336 in Autoimmune Cytopenias

Condition: AIHA - Warm Autoimmune Hemolytic Anemia · AIHA - Cold Autoimmune Hemolytic Anemia · ITP - Immune Thrombocytopenia  ·  Sponsor: Lakefront Biotherapeutics West LLC

PhasePhase 1
Planned participants32
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.

This description comes directly from the study's public registry record.

Talk to the study team

Study Sponsor  ·  415-429-4887  ·  info@ouromeds.com

Always discuss trial participation with your own doctor first.

Locations (3)

The Canberra HospitalCanberra, Australian Capital Territory, AustraliaRecruiting
Liverpool HospitalSydney, New South Wales, AustraliaRecruiting
Icon Cancer Center South BrisbaneBrisbane, Queensland, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07083960